NASDAQ$GOCO

GoHealth Inc · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Announced second quarter 2022 results, with a decrease in net revenue and an increase in medicare submitted policies.

GoHealth reported a decrease in net revenue by 19% compared to the prior year period, totaling $158.7 million. The company experienced a net loss of $113.8 million, a significant increase from the previous year's $39.2 million loss. However, Medicare Submitted Policies increased by 9% compared to the prior year period, reaching 177,911.

  • Medicare Submitted Policies increased 9% compared to the prior year period.
  • Net revenue decreased 19% compared to the prior year period.
  • Net loss significantly increased compared to the prior year period.
  • Adjusted EBITDA decreased compared to the prior year period.

Headline financials

Total Revenue

$159M

Previous: $197M-19.4%
EPS (adj)

-$2.25

Previous: -$1.80-25.0%
Free Cash Flow

-$43.8M

Previous: -$12M-265.5%
Net Income

-$43.8M

Previous: -$12M-265.5%
Operating Income

-$101M

Previous: -$19M-433.2%
Gross Profit

$108M

Previous: $159M-32.5%
Cash & Equivalents

$76.2M

Previous: $113M-32.5%
Total Assets

$1.9B

Previous: $2.11B-10.1%
Stock-Based Comp

$12.1M

Previous: $7.6M+59.7%

Revenue & EPS history

GoHealth · Revenue · Quarterly

$159M

Q2 2022-19.4%vs Q2 2021
Beat estimate in 5 of 14 quarters(36%)
ActualEstimate

Revenue by segment

GoHealth · $11.9M total across 4 segments · Q1 2026

  • Medicare Agency Revenue
    $9.8M
  • Other Non-Agency Revenue
    $1.76M
  • Medicare Non-Agency Revenue
    $200K
  • Other Agency Revenue
    $155K

Forward guidance

GoHealth has suspended the Company’s previously issued quantitative guidance for the remainder of 2022 and expects to achieve cash flow breakeven on a trailing twelve-month basis by the middle of next year.

Tailwinds

  • Renewed focus on high-quality customer experience.
  • Efficiency improvements.
  • Focus on cash flow.
  • Strategic moves, including cost actions, to strengthen ability to achieve cash flow breakeven.
  • Ramping up Encompass programs to be fully deployed for the upcoming AEP.

Headwinds

  • Suspension of previously issued quantitative guidance for the remainder of 2022.
  • Competitive dynamics amongst carrier partners.
  • Evolving needs of Medicare beneficiaries.
  • This quarter’s results do not represent the financial performance they are capable of achieving.
  • facing a natural inflection point

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

-7.7%

Avg return

Earnings day

-9.7%

Avg return

5 days after

-6.6%

Avg return

30 days after

26%

6 / 23 earnings

Positive

+32.2%

Q1 2023

Best reaction

-45.5%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.5%-23.4%
Q3 2025-24.4%-32.0%-12.8%
Q2 2025-9.0%-7.6%-23.8%
Q1 2025-0.6%-17.4%-21.4%
Q4 2024-14.4%-14.9%-32.8%
Q3 2024-6.6%-0.4%-15.4%
Q2 2024-21.4%-28.3%-34.0%
Q1 2024-8.0%-11.1%+2.2%
Q4 2023-13.0%-25.7%-27.0%
Q3 2023+2.3%+6.7%+7.4%
Q2 2023+6.8%+6.3%-17.2%
Q1 2023+32.2%+44.8%+99.5%
Q4 2022-19.9%-6.2%-18.5%
Q3 2022-16.7%-9.4%+95.3%
Q2 2022-31.5%-43.3%-57.0%
Q1 2022+11.1%+4.9%+6.5%
Q4 2021+23.7%+37.7%-9.8%
Q3 2021+1.1%-4.7%-18.1%
Q2 2021-45.5%-42.2%-34.7%
Q1 2021-2.7%-5.6%-4.0%
Q4 2020-14.9%-16.9%-4.1%
Q3 2020-14.9%-15.1%+1.8%
Q2 2020-10.5%-18.5%-27.1%
Q1 2020
Q4 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro